Characteristics | All patients (n = 2002) | Males (n = 1134) (57%) | Females (n = 868) (43%) | |||
---|---|---|---|---|---|---|
Age, yrs | 66.9 | (9.5) | 69.0 | (9.1) | 64.3 | (9.2)* |
Weight, kg | 71.9 | (16.5) | 77.2 | (15.9) | 65.0 | (14.7)* |
Height, m | 1.68 | (0.9) | 1.73 | (0.7) | 1.62 | (0.6)* |
BMI, kg/m2 | 25.4 | (5.2) | 25.8 | (4.9) | 25.0 | (5.5)* |
FFMI, kg/m2 | 17.0 | (2.4) | 18.1 | (2.2) | 15.5 | (1.8)* |
FEV1, % predicted | 48.2 | (23.2) | 47.2 | (20.7) | 49.6 | (26.1)* |
FVC, % predicted | 95.9 | (22.3) | 93.0 | (21.7) | 99.7 | (22.7)* |
FEV1/FVC, r | 39.8 | (11.8) | 38.9 | (11.9) | 40.9 | (11.4)* |
FRC, % predicted | 150.1 | (35.9) | 146.3 | (37.5) | 154.9 | (33.0)* |
DLCO, % predicted | 52.9 | (18.1) | 55.3 | (30.1) | 50.9 | (25.7)* |
PO2, kPa | 9.8 | (2.3) | 9.8 | (2.2) | 9.7 | (2.4) |
PCO2, kPa | 5.3 | (1.4) | 5.2 | (1.2) | 5.4 | (1.5) |
MRC dyspnea grade | 3.3 | (1.1) | 3.3 | (1.1) | 3.4 | (1.0) |
GOLD stage I | 96 | (4.8) | 48 | (4.2) | 48 | (5.5) |
GOLD stage II | 649 | (32.4) | 362 | (31.9) | 287 | (33.1) |
GOLD stage III | 730 | (36.5) | 419 | (36.9) | 311 | (35.8) |
GOLD stage IV | 527 | (26.3) | 305 | (26.9) | 222 | (25.6) |
Receiving LTOT, n, (%) | 408 | (20.4) | 230 | (20.3) | 178 | (20.5) |